Science

Science

Leveraging cutting-edge science and technology to identify and propel best-in-class biologics to the clinic.

Paragon employs a breadth of protein engineering technologies to perform biologics discovery and optimization. We have built a team of exceptional leaders in drug discovery and development who work with top-tier partners to develop transformative programs.

Science

We engineer the best drug candidates by applying high-throughput screening systems and optimization techniques.

Science

Our CMC model enables us to rapidly and reliably progress novel treatments from ideation to the clinic.

Science

Our development process allows us to successfully execute highly efficient program timelines with cutting-edge technologies while ensuring quality is never sacrificed.

Pipeline

Fueling a pipeline of best-in-class therapies for a range of diseases.

Our business model centers on bringing therapies to patients as rapidly as possible—once a program or set of programs achieves significant progress, we enable their advancement to the clinic by launching spinout companies, engaging in partnerships with other biopharma companies, or continuing to shape their development in-house at Paragon. Our product pipeline demonstrates our progress, with the leading program on track to enter clinical trials in 2023—less than two years from its ideation.

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR004 (APG777)

Ind-Enabling

PR001 (APG808)

Ind-Enabling

PR007 (APG990)

Discovery

PR012 (APG222)

Discovery

Rights/Partner

Apogee

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR011 (SPY001)

Ind-Enabling

PR010 (SPY002)

Discovery

PR014 (SPY003)

Discovery

PR015 (SPY004)

Discovery

PR026 (SPY130)

Ind-Enabling

PR022 (SPY120)

Discovery

PR025 (SPY230)

Discovery

Rights/Partner

Spyre Logo

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR002

Discovery

PR013

Discovery

Rights/Partner

Undisclosed

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

PR003

Discovery

PR016

Discovery

Rights/Partner

Paragon

Programs

Discovery

Ind-Enabling

Clinical

Rights/Partner

ADDITIONAL PIPELINE PROGRAMS

Discovery

Paragon is initiating multiple new pipeline programs based on robust biological and clinical validation.

Team

Dedicated experts with a passion for improving health outcomes.

Paragon is led by a collaborative team of innovators with deep expertise in biologics engineering and development. Our collaboration with FairJourney Biologics expands the reach and capabilities of our team through dedicated antibody discovery experts and resources. Together, we are motivated to tackle some of the toughest disease areas and improve quality of life for patients.

Evan Thompson, Ph.D.

CHIEF OPERATING OFFICER

View Bio

Hussam Shaheen, Ph.D.

SENIOR VICE PRESIDENT OF BIOTHERAPEUTICS

View Bio

Jason Oh, Ph.D.

VICE PRESIDENT OF BIOLOGY

View Bio

Shawn Russell, Ph.D.

VICE PRESIDENT OF CMC

View Bio

Cyrus Stacey

VICE PRESIDENT OF QUALITY

View Bio

Neta Batscha

VICE PRESIDENT OF CORPORATE STRATEGY & OPERATIONS

View Bio

Daniel Greenberg

Vice President of Corporate Strategy

View Bio

Yuqi Liu, Ph.D.

DIRECTOR OF PROTEIN SCIENCE

View Bio

Eric Zhu, Ph.D.

DIRECTOR OF BIOTHERAPEUTICS DISCOVERY

View Bio

Byron Kwan, Ph.D.

DIRECTOR OF BIOTHERAPEUTICS

View Bio

Daniel Rios, Ph.D.

DIRECTOR OF BIOLOGY

View Bio

Rita Vaz, Ph.D.

DIRECTOR OF PROGRAM AND ALLIANCE MANAGEMENT

View Bio

M. Murshid Alam, Ph.D.

PRINCIPAL SCIENTIST

View Bio

Jake Milligan, Ph.D.

PRINCIPAL SCIENTIST

View Bio

Byong Ha Kang, Ph.D.

SENIOR SCIENTIST

View Bio

Soraia Oliveira, Ph.D.

Project Manager for Antibody Discovery and Development

View Bio

Joana Ministro, Ph.D.

PROJECT MANAGER FOR ANTIBODY DISCOVERY AND DEVELOPMENT

View Bio

Katie Kelley

CONTROLLER

View Bio

James Nzukie

DIRECTOR OF FINANCE PLANNING & ANALYSIS

View Bio

Sophia Medina

ADMINISTRATIVE ASSISTANT

View Bio
About usAbout us
Fairmount

About Us

Paragon was founded by Fairmount in 2021 as the firm’s discovery engine for best-in-class biologics. Leveraging a dedicated in-house team of scientific experts in antibody development, as well as our partnership with FairJourney Biologics, Paragon pursues unique therapeutic concepts and enables their rapid proof-of-concept validation. Fairmount is dedicated to investing in promising new therapies developed by biotechnology and life science companies and works closely with the Paragon team to provide research and strategic direction.

News

The latest Paragon news and developments.

08.29.2023

Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics

Read More

12.07.2022

Paragon Therapeutics Launches First Spinout, Apogee Therapeutics, to Advance Novel Therapies for Inflammatory and Immunological Conditions

Read More
Join Us

Join Us

Be a part of our innovative team.

We are excited about the future as we advance our state-of-the-art science. Come join our team and help us shape the next generation of biologic treatments.

VIEW POSITIONS ON LINKEDIN

Contact

For media inquiries or more information: